Note: Not guaranteed to come with supplemental materials (access cards, study guides, lab manuals, CDs, etc.)
Extend Your Rental at Any Time
Need to keep your rental past your due date? At any time before your due date you can extend or purchase your rental through your account.
Sorry, this item is currently unavailable.
Ocular angiogenesis, or the abnormal growth of blood vessels in the eye, is the cause of major neovascular eye diseases. In addition, retinal and choroidal neovascularization are the major causes of vision loss in this country. With the new era of anti-angiogenic therapies already in practice, ophthalmologists have started treating many ocular diseases including macular degeneration, diabetic retinopathy, and retinal vascular occlusion using anti-angiogenic drugs. This book covers the basic pathophysiology of ocular angiogenesis and strategies for inhibition. The authors discuss the "Principles" of anti-angiogenic therapy, pre-clinical studies, future drugs on the horizon, drug delivery, and the "Practice" of the therapy in many ocular diseases. Vision researchers in both academia and industry, as well as clinician scientists, have contributed chapters on different aspects of the angiogenic process, and clinical strategies to fight it. The book also includes chapters that deal with diabetic macular edema, and various therapeutic options for this condition. A companion website includes the fully searchable text and an image bank.
Table of Contents
I: PRINCIPLES 1: Tumor Angiogenesis: Concept Judah Folkman (Reproduction of the Hellen Keller Foundation Lecture 2006) 2: Retinal Neovascularization: Pathophysiology Robert Frank 3: Choroidal Neovascularization: Pathophysiology J. Ambati 4: VEGF the Major Player Patricia D'Amore 5: IFG-1 in Angiogenesis Lois Smith 6: Is It All the VEGF? Other Factors John Penn 7: Proteinases and Integrins Alexander Ljubimov and Arup Das 8: Endogenous Inhibitors David Hinton 9: Macular Edema: Molecular Mechanisms Arup Das II: PRACTICE 1: Anti-VEGF Therapies in ARMD in Practice Jeff Heier 2: Novel Anti-VEGF Drugs in ARMD Currently in Trials Quan Nguyen 3: Safety of Anti-VEGF Drugs David Boyer and Thomas Friberg 4: Pharmacokinetics of Anti-VEGF Drugs Karl Casky 5: Anti-VEGF Therapies of Retinal Neovascularization Allen Ho 6: Anti-VEGF Therapies in Diabetic Macular Edema Lloyd Aiello 7: Steroids in ARMD and Macular Edema Jennifer Lim 8: Anti-VEGF Therapies in ROP Antonio Capone 9: Pharmacotherapy in Retinal Vein Occlusions Michael Ip 10: Intravitreal Injection: Technique and Complications Elias Reichel 11: Role of OCT in Management of ARMD and Macular Edema Srinivas Sadda 12: Role of Laser in the Era of Pharmacotherapy Thomas Friberg 13: PDT: Is It an Option? Albert Augustin 14: Combination Therapy: Future Richard Spaide 15: Gene Therapy in Ocular Angiogenesis Rajendra Kumar-Singh 16: Stem Cell Therapy Maria Grant 17: Drug Delivery in Posterior Segment: Challenges Prithvi Mruthyunjaya and Glenn Jaffe 18: Corneal Neovascularization Bala Ambati 19: Neovascular Glaucoma James Tsai 20: Financial Impact of Anti-Angiogenic Therapy George Williams 21: Future of Anti-Angiogenic Therapy Anthony Adamis